GSK adds to its trove of pos­i­tive da­ta for mul­ti­ple myelo­ma con­tender as ri­vals con­tin­ue to com­mand the spot­light

Glax­o­SmithK­line’s can­cer R&D team put up more pos­i­tive num­bers for its ADC be­lan­tam­ab mafodotin, one of its top pipeline prospects.

Flash­ing the re­sults just ahead of a busy AS­CO week­end, Ax­el Hoos and the team not­ed new mul­ti­ple myelo­ma da­ta high­light­ing promis­ing re­spons­es from their open-la­bel DREAMM-6 study — af­ter con­firm­ing the over­all re­sponse rate of 32% among heav­i­ly pre-treat­ed pa­tients re­viewed in DREAMM-2.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER